<DOC>
	<DOCNO>NCT02883660</DOCNO>
	<brief_summary>The purpose study determine whether patient prescribe antidepressant medication experience significant adverse effect likely poor metabolizers CYP450 ( CYP2B6 , CYP2D6 , CYP2C19 , CYP3A4/5+ ) drug metabolize enzyme and/or homozygous short allele serotonin transporter ( SLC6A4 ) compare patient take antidepressant medication experience significant adverse effect also minimal response medication . The target medication study include escitalopram , citalopram , paroxetine , fluvoxamine , venlafaxine , duloxetine , bupropion , vortioxetine , vilazodone , levomilnacipran .</brief_summary>
	<brief_title>Genecept Assay Adverse Effects Antidepressants</brief_title>
	<detailed_description>Genetic variation CYP2B6 , CYP2D6 , CYP2C19 , CYP3A4/5+ drug metabolize enzyme responsible metabolism large number psychiatric nonpsychiatric medication . Variations gene encode enzymes alter activity result unexpectedly high low serum level drug lead potentially change efficacy adverse event . The serotonin transporter protein presynaptic transmembrane protein responsible serotonin reuptake . The `` short '' form serotonin transporter promoter ( SLC6A4 ) associate reduced activity transporter . Patients homozygous `` short '' allele SLC6A4 may likely poor response , slow response , great adverse event serotonergic medication . The target medication study include escitalopram , citalopram , paroxetine , fluvoxamine , venlafaxine , duloxetine , bupropion , vortioxetine , vilazodone , levomilnacipran .</detailed_description>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>1 . Age 18 year old 2 . Able give inform consent prior initiation protocol require procedure . 3 . Subject must able understand nature study , agree comply study procedure , communicate medical history study personnel . 4 . Subject treat one follow `` target antidepressant : '' Escitalopram , citalopram , paroxetine , fluvoxamine , venlafaxine , duloxetine , bupropion , vortioxetine , vilazodone , levomilnacipran . Rationale : These antidepressant primarily metabolize CYP isoenzymes assess . Antidepressants like sertraline , fluoxetine , mirtazapine metabolize multiple CYP isoenzymes therefore less likely significantly affect metabolizer status particular CYP isoenzyme . For patient treated multiple antidepressant , antidepressant associate great overall burden AEs select target antidepressant . 5a . Study group : `` Increased AEs '' currently past one target antidepressant operationally define either A B : A ) One AEs moderate/severe OR three AEs mild occur less usual minimum recommend dose antidepressant , B ) Three AEs moderate/severe OR five AEs mild dose antidepressant within usual recommend dose 5b . Control group : Both A B A . Less 30 % reduction severity depression treatment least 6 week B . Minimal AEs antidepressant 1 . Subjects antidepressant specify inclusion criterion . 2 . Subjects unclear medication cause adverse event 3 . Subjects participation study would detrimental mental physical health base investigator 's opinion 4 . Subjects medical condition , investigator 's judgment , may cause report adverse event 5 . Prisoners patient involuntarily incarcerate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>genetics</keyword>
	<keyword>Antidepressants</keyword>
</DOC>